Alopecia as a Consequence of Tacrolimus Therapy in Renal Transplantation?

Talbot, David; Rix, D.; Abusin, K.; Mirza, Darius; Manas, Derek

doi:10.1097/00007890-199712150-00027

Cited by 16 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of AA in a 76 year‐old‐male patient under treatment with oral tacrolimus, mycophenolic acid and methylprednisolone for 2.5 years after kidney transplantation was unusual. There have been a few case reports on AA onset after organ transplantation under the use of oral tacrolimus, with a delay time varying between 1 year and 7 years 16–19 . The prognosis was generally good.…”

Section: Discussionmentioning

confidence: 99%

Late‐onset alopecia areata: A retrospective study of 73 patients from Taiwan

Yang

Tsai

et al. 2012

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Late‐onset alopecia areata: A retrospective study of 73 patients from Taiwan

Yang

Tsai

et al. 2012

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Tacrolimus-related alopecia was first described by Shapiro et al in 1990, with an incidence of 3-6% (12). Only a few cases have since been discussed in the literature, and the reported frequency of tacrolimus-induced alopecia remains low (6,7). However, the incidence of alopecia is probably underestimated by clinicians.…”

Section: Discussionmentioning

confidence: 99%

“…More specifically, frequently reported adverse events associated with tacrolimus include nephrotoxicity, neurotoxicity, and glycemic disturbances; in contrast, tacrolimus is only rarely associated with the cyclosporine-specific adverse events of gingivitis, gum hyperplasia, and hirsutism. Although alopecia was not initially reported with tacrolimus in liver transplant patients (6,7), a large prospective trial in renal transplant recipients revealed that alopecia occurred in more than 10% of tacrolimustreated patients, whereas 8.7% of patients given cyclosporine experienced hirsutism (8).…”

mentioning

confidence: 99%

Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Despite the similar mechanism of inhibition of calcineurin, tacrolimus gives fewer skin abnormalities and does not cause gingival hyperplasia. However, cases of alopecia [24,25] and severe atopic dermatitis [26]. have been reported in transplant patients treated with tacrolimus.…”

Section: Drug‐related Skin Lesions (Table 1)mentioning

confidence: 99%

Nonneoplastic mucocutaneous lesions in organ transplant recipients

Ponticelli¹,

Bencini²

2011

Transplant International

View full text Add to dashboard Cite

Nonneoplastic cutaneous or mucosal complications are frequent in organ transplant recipients. In a systematic overview made in Leiden, 591 nonmalignant skin diseases were registered in 1768 (33%) organ transplant recipients followed over 13 years [1]. Smaller series reported that the prevalence of nonmalignant skin lesions in transplant recipients may range between 49% and 87% [2][3][4][5]. The lesions are mainly related to the prolonged use of immunosuppressive drugs, but an important contributing role may also be played by exposure to sunlight and viral infections. Although the pathogenesis of these lesions is often multifactorial, we will separate them into lesions caused by drugs and by infections.Drug-related skin lesions (Table 1) Calcium channel blockers can cause some cutaneous abnormalities, including photo-damage of the head and neck, teleangiectasia, and solar elastosis [6] as well as gingival hyperplasia [7]. However, most skin lesions in renal transplant recipients are caused by immunosuppressive drugs, in particular glucocorticoids and cyclosporine. An important consequence of the esthetic changes caused by these agents is a poor adherence to treatment which represents a major cause of graft failure [8]. GlucocorticoidsRenal transplant recipients given glucocorticoids may show a number of dermatological lesions which are related to the doses and the time of exposure of these agents. While the doses of glucocorticoids used in transplantation were very high in the recent past, the current immunosuppression is based on low doses of glucocorticoids and some units even treat transplant recipients with steroid-free regimens. As a consequence, the skin changes Keywords fungal infections, mucocutaneous lesions, transplant complications, transplantation and skin lesions. CorrespondenceClaudio Ponticelli MD, Istituto Scientifico Humanitas,

show abstract

Alopecia as a Consequence of Tacrolimus Therapy in Renal Transplantation?

Cited by 16 publications

References 5 publications

Late‐onset alopecia areata: A retrospective study of 73 patients from Taiwan

Late‐onset alopecia areata: A retrospective study of 73 patients from Taiwan

Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients

Nonneoplastic mucocutaneous lesions in organ transplant recipients

Contact Info

Product

Resources

About